<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id><journal-id journal-id-type="hwp">bmjopen</journal-id><journal-id journal-id-type="publisher-id">bmjopen</journal-id><journal-title-group><journal-title>BMJ Open</journal-title></journal-title-group><issn pub-type="epub">2044-6055</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23892369</article-id><article-id pub-id-type="pmc">3731725</article-id><article-id pub-id-type="publisher-id">bmjopen-2013-002665</article-id><article-id pub-id-type="doi">10.1136/bmjopen-2013-002665</article-id><article-categories><subj-group subj-group-type="heading"><subject>Infectious Diseases</subject><subj-group><subject>Research</subject></subj-group></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject><subject>1705</subject><subject>1706</subject><subject>1732</subject></subj-group></article-categories><title-group><article-title>Autoantibody prevalence in active tuberculosis: reactive or pathognomonic?</article-title><alt-title alt-title-type="short">Immune interaction between chronic active infection and autoimmunity</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shen</surname><given-names>Chieh-Yu</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hsieh</surname><given-names>Song-Chou</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Chia-Li</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jann-Yuan</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Li-Na</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Chong-Jen</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>Department of Internal Medicine</addr-line>, <institution>National Taiwan University Hospital</institution>, <addr-line>Taipei</addr-line>, <country>Taiwan</country></aff><aff id="af2"><label>2</label><addr-line>Department of Laboratory Medicine</addr-line>, <institution>National Taiwan University Hospital</institution>, <addr-line>Taipei</addr-line>, <country>Taiwan</country></aff><author-notes><corresp><label>Correspondence to</label> Dr Jann-Yuan Wang; <email>jywang@ntu.edu.tw</email></corresp></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>25</day><month>7</month><year>2013</year></pub-date><volume>3</volume><issue>7</issue><elocation-id>e002665</elocation-id><history><date date-type="received"><day>31</day><month>1</month><year>2013</year></date><date date-type="rev-recd"><day>14</day><month>5</month><year>2013</year></date><date date-type="accepted"><day>12</day><month>6</month><year>2013</year></date></history><permissions><copyright-statement>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access"><license-p>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="bmjopen-2013-002665.pdf"/><self-uri content-type="draft-revisions-pdf" xlink:type="simple" xlink:href="bmjopen-2013-002665.draft_revisions.pdf"/><self-uri content-type="reviewers-comments-pdf" xlink:type="simple" xlink:href="bmjopen-2013-002665.reviewer_comments.pdf"/><abstract><sec><title>Objectives</title><p>To evaluate the autoantibody in patients without corresponding symptoms, whether these autoantibody are pathognomonic or not. We hypothesised that autoantibody may be reactive to chronic infection, such as tuberculosis (TB).</p></sec><sec><title>Design</title><p>Randomised, case&#x02013;control cohort study.</p></sec><sec><title>Setting</title><p>A tertiary centre in Taiwan.</p></sec><sec><title>Participants</title><p>We randomly chose 100 patients out of the data bank of patients with TB in a tertiary medical centre. All patients completed the sera sampling. We chose 100 patients according to autoantibody prevalence in previous literature. We also chose 100 medical staff as control group.</p></sec><sec><title>Interventions</title><p>We tested anti-SSA, anti-SSB, anti-Sm, anti ribonucleoprotein, anti-Scl 70, anticentromere, anti-double-stranded DNA, anticardiolipin IgG and IgM in all patient and control groups. The clinical symptoms and the underlying disease were all recorded.</p></sec><sec><title>Primary and secondary outcome measures</title><p>The result of sera antibody titre was recorded. For those with specific positive serology results, following examination was carried out after a 3-month anti-TB medication.</p></sec><sec><title>Results</title><p>Anticardiolipin IgG titre was significantly higher in patients with TB than in control group. We compared the result with previous population study and found that anti-Scl70 is also significantly higher in patients with TB. The following up data in anti-Scl70 revealed decreased titre after treatment. No correlation between sera titre and clinical conditions was observed.</p></sec><sec><title>Conclusions</title><p>In TB endemic areas, a significant proportion (32%) of patients with TB have elevated autoantibody titres, especially anticardiolipin IgG and anti-Scl-70. Mycobacterial studies should be performed in patients with elevated serum autoantibody titres but without the typical or multiple manifestations of autoimmune diseases.</p></sec><sec><title>Trial registration</title><p>The study was approved by the Institutional Review Board of the hospital (NTUH REC: 9561707008) after informed consent had been obtained from the patients.</p></sec></abstract><kwd-group><kwd>Rheumatology</kwd><kwd>Immunology</kwd></kwd-group></article-meta></front><body><boxed-text position="float"><caption><title>Article summary</title></caption><sec><title>Article focus</title><list list-type="bullet"><list-item><p>As chronic active tuberculosis (TB) has immunogenicity, autoantibodies are often found in patients with TB. Are there disease-specific autoantibodies in these patients? Are these autoantibodies pathognomonic even without the attendant symptomatology? Do they require immunosuppressant therapy? Can these disease-specific autoantibodies be reactive to stimulation like TB even without corresponding symptoms?</p></list-item></list></sec><sec><title>Key message</title><list list-type="bullet"><list-item><p>Disease-specific autoantibodies other than rheumatoid factor or antinuclear antibody exist in patients with TB. Autoantibody titres may decrease, even return to normal, as the infection is controlled. These findings suggest that autoantibodies are reactive to TB instead of being pathognomonic, and do not require immunosuppressant therapy.</p></list-item></list></sec><sec><title>Strengths and limitations of this study</title><list list-type="bullet"><list-item><p>This is the first study to evaluate the clinical significance of autoantibodies by sequential data in TB. Despite the high probability of TB exposure and infection, medical staff serving as control patients may have higher prevalences of autoantibodies.</p></list-item></list></sec></boxed-text><sec id="s1"><title>Introduction</title><p>Tuberculosis (TB) has become one of the most important diseases in the past two decades. It leads to organ dysfunction, mortality and various clinical manifestations. Previous studies have shown that sera from patients with active TB may contain autoantibodies that are unique in autoimmune diseases. The reported autoantibodies include rheumatoid factor (RF), antinuclear antibody (ANA), anticardiolipin antibody (ACA; IgM isotype predominant), antineutrophil cytoplasmic antibodies (ANCA) and anticyclic citrullinated peptide.<xref ref-type="bibr" rid="R1 R2 R3 R4">1&#x02013;4</xref> Some of these are hallmarks of certain autoimmune diseases like rheumatoid arthritis, systemic lupus erythematosus (SLE) and ANCA-associated vasculitis. Some are even disease-specific, such as anticyclic citrullinated peptide in rheumatoid arthritis.<xref ref-type="bibr" rid="R5">5</xref>
<xref ref-type="bibr" rid="R6">6</xref> However, most studies are cross-sectional with limited case numbers and without definite correlations between serology and clinical manifestations. Little is known on the clinical significance (ie, pathognomonic, reactive or incidental) of autoantibodies in TB and the necessity of corticosteroid therapy.</p><p>Since patients with TB present with non-specific symptoms like fever, malaise and weight loss, clinicians may simultaneously order mycobacterial studies (acid-fast smear and mycobacterial culture) and autoimmune serology. Results of the latter usually become available earlier than results of the former. Thus, some patients with TB are put on systemic corticosteroids rather than anti-TB treatment, rendering the further dissemination of <italic>Mycobacterium tuberculosis</italic> bacilli. In this prospective cohort study, the prevalence of autoantibodies in patients with active TB was evaluated and compared with those of healthy controls. Dynamic changes in the autoantibodies were also monitored to investigate their clinical significance in patients with TB.</p></sec><sec sec-type="methods" id="s2"><title>Patients and methods</title><sec id="s2a"><title>Patients and the study protocol</title><p>The Institutional Review Board of the National Taiwan University Hospital (NTUH) approved this study (NTUH REC: 9561707008). To have a power of 0.8 and an &#x003b1; error of 0.95 in a two-sided test where the prevalence of ANA in patients with TB and the general population was 33% and 20%, respectively,<xref ref-type="bibr" rid="R1">1</xref> the calculated sample size was 83 for each. Therefore, from the 933 new cases of culture-confirmed TB, diagnosed at the NTUH between January 2007 and December 2009, 100 were enrolled. All of the study participants provided written informed consent.</p><p>Among the 100 patients with TB, 96 had pure pulmonary TB, two had concomitant pulmonary and extrapulmonary TB (peritonitis in one and meningitis in another) and two had extrapulmonary TB only (neck lymphadenopathy in one and cutaneous TB in another). The first serum samples were collected before the start of anti-TB treatment. Blood was examined for autoantibodies to the Ro antigen, La antigen, centromere protein, double-stranded DNA (dsDNA), topoisomerase I (Scl-70), Smith protein, ribonucleoprotein particle (RNP), histone protein and histidyl-transfer RNA synthetase (Jo1). Anticardiolipin IgG and anticardiolipin IgM were also examined. For those with elevated serum autoantibody levels, follow-up serum samples were collected 3&#x02005;months after anti-TB treatment to evaluate its effect on the autoantibody titres.</p><p>All of patients with TB received standard anti-TB treatment consisting of daily isoniazid (INH), rifampin (RIF), ethambutol and pyrazinamide in the first 2&#x02005;months, followed by daily INH and RIF for the next 4&#x02005;months.<xref ref-type="bibr" rid="R7">7</xref> The regimen was modified by the primary care physician if necessary. One hundred healthy medical staff members were enrolled as the control group.</p><p>The clinical parameters collected were age, sex, underlying disease, clinical manifestations and radiographic findings of TB, as well as adverse events during anti-TB treatment. Respiratory symptoms included cough, sputum, haemoptysis, dyspnoea and chest pain, while constitutional symptoms were fever, weight loss, general malaise and night sweats. The adverse events were classified into seven categories: (1) rheumatological, including cutaneous reaction and arthralgia; (2) gastrointestinal, including abnormal liver function, gastric discomfort, abdominal pain and change in bowel movement; (3) constitutional, including fever, poor appetite and malaise; (4) renal, including hyperuricaemia and impaired renal function; (5) neurological, including blurred vision, insomnia, delirium, headache and numbness; (6) respiratory, including cough, dyspnoea and chest pain and (7) haematological, including leukopenia, thrombocytopenia and anaemia.</p><p>As latent TB infection was more common in the medical staff than in the general population,<xref ref-type="bibr" rid="R8">8</xref> 100 healthcare workers were recruited as the control group for comparison. Household contacts of patients with TB might also have a high probability of latent TB infection but if relatives were used as control,<xref ref-type="bibr" rid="R9">9</xref> the results might be confounded by similar environment and genetic components as the TB cases.</p></sec><sec id="s2b"><title>Detection of autoantibodies</title><p>A commercial test system AtheNA Multi-Lyte ANA-II Plus Test System was used to test IgG class antiextractable nuclear antigens, including autoantibodies to the Ro antigen, La antigen, centromere protein, dsDNA, Scl-70, Smith protein, RNP, histone protein and Jo1. Serum samples were prepared at 1:21 dilution and ELISA was performed according to the manufacturer's instructions.</p><p>A commercially available kit QUANTA Lite ACA IgM III was used to test anticardiolipin IgM. Sera were prepared at 1:101 dilution. The commercial kit Phadia Varelisa Cardiolipin IgG Antibodies EIA kit was used to test anticardiolipin IgG at serum dilution of 1:101. All ELISA assays were performed according to the manufacturers&#x02019; instructions.</p></sec><sec id="s2c"><title>Statistical analysis</title><p>Intergroup difference was calculated using independent-samples t test for continuous variables and &#x003c7;<sup>2</sup> test or Fisher's exact test for categorical variables, as appropriate. Statistical significance was set at p&#x0003c;0.05. All analyses were performed using the SPSS software V.12.0 for Windows.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>The clinical characteristics of the 100 patients with TB were summarised in <xref ref-type="table" rid="BMJOPEN2013002665TB1">table 1</xref>. The median age was 63&#x02005;years (range, 19&#x02013;92&#x02005;years), with a male-to-female ratio of 2.03. Forty-one patients with TB had underlying diseases such as malignancy (n=17), diabetes mellitus (n=14), end-stage renal disease (n=9) and one each with SLE, ankylosing spondylitis and rheumatoid arthritis. Among the 17 patients with TB with malignancies, 6 had lung cancer, 3 had haematological malignancies, 4 had airway and lung malignancies, 2 had prostate cancer, 1 had breast cancer and 1 had pancreatic cancer.</p><table-wrap id="BMJOPEN2013002665TB1" position="float"><label>Table&#x000a0;1</label><caption><p>Clinical characteristics of patients with autoantibody-positive and autoantibody-negative tuberculosis</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char=" " span="1"/><col align="char" char=" " span="1"/><col align="char" char="." span="1"/></colgroup><thead valign="bottom"><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Autoantibody-positive (n=32)</th><th align="left" rowspan="1" colspan="1">Autoantibody-negative (n=68)</th><th align="left" rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Respiratory symptoms</td><td rowspan="1" colspan="1">22 (69)</td><td rowspan="1" colspan="1">46 (68)</td><td rowspan="1" colspan="1">0.912</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Cough</td><td rowspan="1" colspan="1">9 (28)</td><td rowspan="1" colspan="1">16 (23)</td><td rowspan="1" colspan="1">0.621</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Sputum</td><td rowspan="1" colspan="1">4 (13)</td><td rowspan="1" colspan="1">13 (19)</td><td rowspan="1" colspan="1">0.411</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Haemoptysis</td><td rowspan="1" colspan="1">2 (6)</td><td rowspan="1" colspan="1">3 (4)</td><td rowspan="1" colspan="1">0.654</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Dyspnoea</td><td rowspan="1" colspan="1">5 (16)</td><td rowspan="1" colspan="1">10 (15)</td><td rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Chest pain</td><td rowspan="1" colspan="1">2 (6)</td><td rowspan="1" colspan="1">4 (6)</td><td rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td rowspan="1" colspan="1">Constitutional symptoms</td><td rowspan="1" colspan="1">14 (44)</td><td rowspan="1" colspan="1">21 (31)</td><td rowspan="1" colspan="1">0.208</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Fever</td><td rowspan="1" colspan="1">5 (16)</td><td rowspan="1" colspan="1">9 (13)</td><td rowspan="1" colspan="1">0.763</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Weight loss</td><td rowspan="1" colspan="1">4 (13)</td><td rowspan="1" colspan="1">6 (9)</td><td rowspan="1" colspan="1">0.722</td></tr><tr><td rowspan="1" colspan="1">&#x02003;General malaise</td><td rowspan="1" colspan="1">3 (9)</td><td rowspan="1" colspan="1">3 (4)</td><td rowspan="1" colspan="1">0.381</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Night sweating</td><td rowspan="1" colspan="1">2 (6)</td><td rowspan="1" colspan="1">3 (4)</td><td rowspan="1" colspan="1">0.654</td></tr><tr><td colspan="4" rowspan="1">Sputum smear grading</td></tr><tr><td rowspan="1" colspan="1">&#x02003;3+ &#x0223c; 4+</td><td rowspan="1" colspan="1">2 (6)</td><td rowspan="1" colspan="1">8 (12)</td><td rowspan="1" colspan="1">0.495</td></tr><tr><td rowspan="1" colspan="1">&#x02003;1+ &#x0223c; 2+</td><td rowspan="1" colspan="1">6 (19)</td><td rowspan="1" colspan="1">15 (22)</td><td rowspan="1" colspan="1">0.705</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Negative</td><td rowspan="1" colspan="1">24 (69)</td><td rowspan="1" colspan="1">45 (66)</td><td rowspan="1" colspan="1">0.373</td></tr><tr><td rowspan="1" colspan="1">Serum albumin &#x0003c;3.5&#x02005;g/dL</td><td rowspan="1" colspan="1">6 (19)</td><td rowspan="1" colspan="1">7 (10)</td><td rowspan="1" colspan="1">0.339</td></tr><tr><td colspan="4" rowspan="1">Radiographic findings</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Bilateral infiltration</td><td rowspan="1" colspan="1">10 (31)</td><td rowspan="1" colspan="1">34 (50)</td><td rowspan="1" colspan="1">0.078</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Cavitations</td><td rowspan="1" colspan="1">1 (3)</td><td rowspan="1" colspan="1">8 (12)</td><td rowspan="1" colspan="1">0.265</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Pleural effusion</td><td rowspan="1" colspan="1">5 (16)</td><td rowspan="1" colspan="1">11 (16)</td><td rowspan="1" colspan="1">0.944</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Miliary lesion</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3 (4)</td><td rowspan="1" colspan="1">0.549</td></tr></tbody></table><table-wrap-foot><fn><p>Data are number (%).</p></fn></table-wrap-foot></table-wrap><p>The SLE patient was a middle-aged woman who presented as polyarthritis, malar rash and positive anti-dsDNA and antinuclear antibodies. She received disease-modifying antirheumatic drugs (DMARDs) and corticosteroids. The patient with ankylosing spondylitis was a young woman diagnosed by clinical symptoms and positive HLA-B27. She received non-steroidal anti-inflammatory drugs (NSAIDs). The patient with rheumatoid arthritis was a young woman with symmetric polyarthritis with positive RF. She received DMARDs and NSAIDs. Before the diagnosis of pulmonary TB, results of autoantibody tests were all negative in these three patients.</p><p>Thirty-two patients with TB had elevated serum autoantibody levels, including nine with more than one autoantibody (<xref ref-type="table" rid="BMJOPEN2013002665TB1">table 1</xref>). The clinical manifestations and radiographic findings of the autoantibody-positive and antibody-negative groups were similar. Cough and sputum production were the most common respiratory symptoms, while fever and weight loss were the most common constitutional symptoms. Thirty-one patients were sputum smear positive for acid-fast bacilli.</p><p>Detailed results of the autoantibody tests were shown in <xref ref-type="table" rid="BMJOPEN2013002665TB2">table 2</xref>. The most prevalent autoantibodies in patients with TB were anti-Scl-70, antihistone and anticardiolipin IgG. A significantly higher proportion of patients with TB had elevated serum anticardiolipin IgG titres than the healthy controls (p&#x0003c;0.001). Compared with a previous report on the prevalence of autoantibodies in the general population,<xref ref-type="bibr" rid="R10">10</xref> patients with TB were more likely to have elevated serum titres of anti-Scl-70 (p&#x0003c;0.05) and anticardiolipin IgG (p&#x0003c;0.001). Among the anti-Scl-70-positive and anti-Scl-70-negative groups, 16% and 9%, respectively, had pulmonary cavitation (p=0.441) and 33% and 16%, respectively, had pleural effusion (p=0.245).</p><table-wrap id="BMJOPEN2013002665TB2" position="float"><label>Table&#x000a0;2</label><caption><p>Prevalences of autoantibodies in patient with tuberculosis (TB), healthy controls and the general population<xref ref-type="bibr" rid="R10">10</xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th rowspan="1" colspan="1"/><th align="left" colspan="2" rowspan="1">Normal population<break/>(n=2181)<hr/></th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="left" colspan="3" rowspan="1">p Value<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">Autoantibody</th><th align="left" rowspan="1" colspan="1">ELISA-pos</th><th align="left" rowspan="1" colspan="1">Percentage of pos</th><th align="left" rowspan="1" colspan="1">Patients with TB<break/>(n=100)</th><th align="left" rowspan="1" colspan="1">Healthy control<break/>(n=100)</th><th align="left" rowspan="1" colspan="1">3 Group</th><th align="left" rowspan="1" colspan="1">TB vs normal</th><th align="left" rowspan="1" colspan="1">TB vs control</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Anti-Ro</td><td rowspan="1" colspan="1">58</td><td rowspan="1" colspan="1">2.7</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0.855</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Anti-La</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.795</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Anti-RNP</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">0.5</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.138</td><td rowspan="1" colspan="1">0.108</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Anti-Sm</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Anti-Scl-70</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.498</td></tr><tr><td rowspan="1" colspan="1">Anti-Jo1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.044</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Anti-dsDNA</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">0.5</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.579</td><td rowspan="1" colspan="1">0.39</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Anticentromere</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">1.4</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0.101</td><td rowspan="1" colspan="1">0.059</td><td rowspan="1" colspan="1">0.683</td></tr><tr><td rowspan="1" colspan="1">Antihistone</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.323</td></tr><tr><td rowspan="1" colspan="1">Anticardiolipin IgM</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.297</td></tr><tr><td rowspan="1" colspan="1">Anticardiolipin IgG</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.001</td></tr></tbody></table></table-wrap><p>The median age of the healthy controls was 30&#x02005;years, with a male-to-female ratio of 0.33. None had underlying diseases. Though not statistically significant, the control group had a higher prevalence of anticardiolipin IgM than the TB group (<xref ref-type="table" rid="BMJOPEN2013002665TB2">table 2</xref>). Of the 10 healthy controls positive for anticardiolipin IgM, 8 had borderline titres that just passed the cut-off value. Among them, one was positive for anti-RNP and another for anti-histone antibodies. Of the six patients with TB positive for anticardiolipin IgM, four had borderline titres and one was positive for antihistone antibody.</p><p>Within 3&#x02005;months of anti-TB treatment, 61 patients had 148 adverse events (<xref ref-type="table" rid="BMJOPEN2013002665TB3">table 3</xref>). The most common were rheumatological events, followed by gastrointestinal events. There was no significant difference in adverse events between patients with autoantibody-positive and autoantibody-negative TB.</p><table-wrap id="BMJOPEN2013002665TB3" position="float"><label>Table&#x000a0;3</label><caption><p>Adverse events during anti-tuberculosis (TB) treatment in patients with autoantibody-positive and antibody-negative TB</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Autoantibody-positive (n=32)</th><th align="left" rowspan="1" colspan="1">Autoantibody-negative (n=68)</th><th align="left" rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Rheumatological events</td><td rowspan="1" colspan="1">10 (31)</td><td rowspan="1" colspan="1">28 (41)</td><td rowspan="1" colspan="1">0.340</td></tr><tr><td rowspan="1" colspan="1">Gastrointestinal events</td><td rowspan="1" colspan="1">9 (28)</td><td rowspan="1" colspan="1">22 (32)</td><td rowspan="1" colspan="1">0.670</td></tr><tr><td rowspan="1" colspan="1">Neurological events</td><td rowspan="1" colspan="1">8 (25)</td><td rowspan="1" colspan="1">16 (24)</td><td rowspan="1" colspan="1">0.872</td></tr><tr><td rowspan="1" colspan="1">Renal events</td><td rowspan="1" colspan="1">7 (22)</td><td rowspan="1" colspan="1">19 (28)</td><td rowspan="1" colspan="1">0.519</td></tr><tr><td rowspan="1" colspan="1">Constitutional events</td><td rowspan="1" colspan="1">4 (13)</td><td rowspan="1" colspan="1">19 (28)</td><td rowspan="1" colspan="1">0.087</td></tr><tr><td rowspan="1" colspan="1">Respiratory events</td><td rowspan="1" colspan="1">2 (6)</td><td rowspan="1" colspan="1">3 (4)</td><td rowspan="1" colspan="1">0.654</td></tr><tr><td rowspan="1" colspan="1">Haematological events</td><td rowspan="1" colspan="1">1 (3)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.320</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Total number of events</td><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">107</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Data are number (%).</p></fn><fn><p>TB, tuberculosis.</p></fn></table-wrap-foot></table-wrap><p>For the 11 patients with elevated anticardiolipin IgG and 6 patients with elevated anti-Scl-70 at baseline, serum titres were followed up after 3&#x02005;months of anti-TB treatment (<xref ref-type="table" rid="BMJOPEN2013002665TB4">table 4</xref>). None of the patients received immunosuppressants and DMARDs. Follow-up serum titres of anticardiolipin IgG and anti-Scl-70 returned to normal limits in seven and four patients, respectively. Among the five patients with persistently elevated anticardiolipin IgG or anti-Scl-70 autoantibodies, none had rheumatological symptoms at the end of the 6-month anti-TB treatment.</p><table-wrap id="BMJOPEN2013002665TB4" position="float"><label>Table&#x000a0;4</label><caption><p>Serum autoantibody titres in patients with TB before and after anti-TB treatment</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead valign="bottom"><tr><th rowspan="1" colspan="1"/><th align="left" colspan="2" rowspan="1">Anti-Scl-70<hr/></th><th rowspan="1" colspan="1"/><th align="left" colspan="2" rowspan="1">ACA-IgG<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">Patient No.</th><th align="left" rowspan="1" colspan="1">Initial</th><th align="left" rowspan="1" colspan="1">Follow-up</th><th align="left" rowspan="1" colspan="1">Patient No.</th><th align="left" rowspan="1" colspan="1">Initial</th><th align="left" rowspan="1" colspan="1">Follow-up</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">137</td><td rowspan="1" colspan="1">155</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">18.1</td><td rowspan="1" colspan="1">9.3</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">33.2</td><td rowspan="1" colspan="1">2.6</td></tr><tr><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">156</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">12.3</td><td rowspan="1" colspan="1">4.1</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">14.1</td><td rowspan="1" colspan="1">6.7</td></tr><tr><td rowspan="1" colspan="1">51</td><td rowspan="1" colspan="1">125</td><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">55</td><td rowspan="1" colspan="1">10.8</td><td rowspan="1" colspan="1">13.4</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">23.8</td><td rowspan="1" colspan="1">2.6</td></tr><tr><td rowspan="1" colspan="1">64</td><td rowspan="1" colspan="1">152</td><td rowspan="1" colspan="1">55</td><td rowspan="1" colspan="1">62</td><td rowspan="1" colspan="1">31.1</td><td rowspan="1" colspan="1">4.8</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">18.9</td><td rowspan="1" colspan="1">30.9</td></tr><tr><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">154</td><td rowspan="1" colspan="1">79</td><td rowspan="1" colspan="1">81</td><td rowspan="1" colspan="1">14.6</td><td rowspan="1" colspan="1">23.5</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">92</td><td rowspan="1" colspan="1">21.2</td><td rowspan="1" colspan="1">21.1</td></tr><tr><td rowspan="1" colspan="1">91</td><td rowspan="1" colspan="1">153</td><td rowspan="1" colspan="1">68</td><td rowspan="1" colspan="1">94</td><td rowspan="1" colspan="1">12.8</td><td rowspan="1" colspan="1">5.1</td></tr></tbody></table><table-wrap-foot><fn><p>Normal reference values for anti-Scl-70 and ACA-IgG are &#x0003c;100&#x02005;U/mL and &#x0003c;10 GPL, respectively.</p></fn><fn><p>ACA, anti-cardiolipin antibody; TB, tuberculosis.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>The present study has three important findings. First, one-third of patients with active TB had elevated serum autoantibodies. The prevalences of their autoantibodies, especially anticardiolipin IgG and anti-Scl-70, were significantly higher than those of the general population.<xref ref-type="bibr" rid="R10">10</xref> Second, consistent with previous studies,<xref ref-type="bibr" rid="R1 R2 R3 R4">1&#x02013;4</xref> the presence of autoantibodies neither altered the clinical manifestations and radiographic findings of active TB nor changed the risk of developing adverse events during anti-TB treatment. Third, the elevated autoantibody levels returned to normal limits simply by anti-TB treatment and not by immunosuppressive therapy. These findings suggest that increased serum autoantibodies during active TB may not be diagnostic of autoimmune diseases. Clinical correlation and follow-up are still necessary.</p><p>Autoantibodies come from a break in self-tolerance whereby fragments of mixed self-antigens and pathogen antigens may induce immune response, as in a mode of epitope spread and autoantibody production.<xref ref-type="bibr" rid="R11">11</xref>
<xref ref-type="bibr" rid="R12">12</xref> Epitope spread occurs when there is chronic inflammation, causing the immune system to produce a variety of antibodies against pathogens of chronic infections. Active TB is one of the most common infectious diseases causing long-term inflammation and tissue destruction. Thus, it is reasonable that autoantibodies are more common in patients with TB.</p><p>Clinically detectable autoantibodies are often characteristic of certain autoimmune diseases.<xref ref-type="bibr" rid="R13">13</xref> However, like in other clinical examinations, all autoantibodies should be tested based on the corresponding clinical symptoms and signs. Most autoantibodies are pathognomonic of certain conditions, such as anti-dsDNA in SLE,<xref ref-type="bibr" rid="R14">14</xref> anticyclic citrullinated peptide antibody in rheumatoid arthritis,<xref ref-type="bibr" rid="R6">6</xref>
<xref ref-type="bibr" rid="R15">15</xref> anti-Scl-70 in systemic sclerosis<xref ref-type="bibr" rid="R16">16</xref> and anti-Jo-1 in polymyositis.<xref ref-type="bibr" rid="R17">17</xref> However, autoantibodies may also be present in conditions other than autoimmune diseases, especially when there are no corresponding clinical symptoms, such as RF in infective endocarditis<xref ref-type="bibr" rid="R18">18</xref> and antiphospholipid syndrome secondary to infection or malignancy.<xref ref-type="bibr" rid="R19">19</xref></p><p>The high prevalence of serum autoantibodies in active patients with TB has rarely been investigated and thus, remains unclear. If the autoantibodies are pathognomonic, there should be corresponding rheumatological symptoms and signs, especially in those with specific antiextractable nuclear antigen antibodies. Since the presence of autoantibodies does not alter the clinical manifestations and radiographic presentations of active TB, it is unlikely that autoantibodies have a pathognomonic role.<xref ref-type="bibr" rid="R1 R2 R3 R4">1&#x02013;4</xref> In autoimmune diseases, serology titres of autoantibodies often change along with disease activity, such as anti-dsDNA in lupus nephritis.<xref ref-type="bibr" rid="R14">14</xref> However, the finding that autoantibody titres return to normal limits after anti-TB treatment in more than two-thirds of patients with TB suggests the opposite&#x02014;that the increase in autoantibodies is a reactive change during the disease course of active TB. This is a very important reminder.</p><p>If a patient has elevated autoantibody levels but no typical or multiple rheumatological symptoms, other possible aetiologies should be considered. For a patient in TB endemic areas, sputum samples for acid-fast smear and mycobacterial culture should be performed. If TB is missed and patients are diagnosed as having autoimmune diseases and treated with systemic corticosteroids, disseminated TB and TB-related mortality may occur.</p><p>The association of active TB and anticardiolipin IgG and antitopoisomerase I has not been previously reported. ACA is one of the hallmarks of antiphospholipid syndrome, which is known to be secondary to infectious diseases.<xref ref-type="bibr" rid="R19">19</xref> Such antibody may be triggered by an infectious process that is non-&#x003b2;<sub>2</sub>-glycoprotein 1-dependent. In active TB, mycobacterial phenolic glycolipids may activate neutrophils and release containers of ectosomes.<xref ref-type="bibr" rid="R20">20</xref>
<xref ref-type="bibr" rid="R21">21</xref> Vesicles released from activated neutrophils that express phosphatidylserine and annexin V may be the epitopes of antiphospholipid antibodies.<xref ref-type="bibr" rid="R22">22</xref>
<xref ref-type="bibr" rid="R23">23</xref> This may explain the high prevalence of anticardiolipin IgG in patients with TB. In general, the transient positivity of antiphospholipid antibody is not considered pathognomonic and does not meet the diagnostic criteria of antiphospholipid syndrome.<xref ref-type="bibr" rid="R19">19</xref></p><p>However, some studies have different findings and show that patients with TB with diffuse alveolar haemorrhage have transient anticardiolipin IgG positivity.<xref ref-type="bibr" rid="R24">24</xref>
<xref ref-type="bibr" rid="R25">25</xref> Moreover, in the present study, anticardiolipin IgG remained elevated in 4 of 11 patients even after 3&#x02005;months of anti-TB treatment. Although anticardiolipin IgG is not diagnostic, a high index of suspicion should be maintained regarding their clinical manifestations, including thrombosis, haemorrhage, haemolytic anaemia and thrombocytopenia<xref ref-type="bibr" rid="R19">19</xref>
<xref ref-type="bibr" rid="R26">26</xref> in patients with TB with elevated anticardiolipin IgG.</p><p>Anti-Scl-70 is the first known prevalent autoantibody in patients with progressive systemic sclerosis. The autoantibody targets an antigen that is a 70&#x02005;kDa protein. Later studies reveal that Scl-70 should be the nuclear DNA topoisomerase I.<xref ref-type="bibr" rid="R27">27</xref>
<xref ref-type="bibr" rid="R28">28</xref> Topoisomerase I is an enzyme that relaxes the strain on DNA by nicking and ligating it. One of the notorious manifestations of systemic sclerosis is interstitial lung disease, characterised by lung fibrosis.<xref ref-type="bibr" rid="R29">29</xref> Although there is no significant difference, patients with TB in this study have elevated anti-Scl 70 and higher risk of pulmonary cavitation and pleural effusion. The underlying mechanisms involved are unclear since antigenic topoisomerase I is not a component of leukocyte ectosome.<xref ref-type="bibr" rid="R21">21</xref> Moreover, it is not released from the TB bacilli because the structure of mycobacterial topoisomerase I is different from those of humans.<xref ref-type="bibr" rid="R30">30</xref>
<xref ref-type="bibr" rid="R31">31</xref></p><p>In the present study, anti-Scl-70 titres returned to normal range after anti-TB treatment in all except one patient. The anti-Scl-70 antibody in active TB is probably secondary to pulmonary inflammation and destruction, which is uncovered by the nuclear topoisomerase I, thereby triggering the production of autoimmunity. The titre decreases once pulmonary injury is alleviated.</p><p>This study has some limitations. First, because the control group was composed of medical staff members, their baseline characteristics were very different from those of the TB group. This might lead to uncertainty in the prevalence of autoantibody in non-TB groups. Nonetheless, the autoantibody prevalence was still higher in patients with TB than in the general population reported in a previous publication.<xref ref-type="bibr" rid="R10">10</xref> Second, follow-up samples were only obtained in those with elevated serum levels of autoantibodies before anti-TB treatment. Dynamic changes in autoantibodies might have been missed.</p><p>TB has a kaleidoscope of presentations that constantly challenge physicians. In TB endemic areas, a significant proportion (32%) of patients with TB has elevated autoantibody titres, especially anticardiolipin IgG and anti-Scl-70. This phenomenon is likely to be reactive due to the lack of clinical correlations, as well as the spontaneous regression after TB treatment. Mycobacterial studies should be performed in patients with elevated serum autoantibody titres but without the typical or multiple manifestations of autoimmune diseases.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="d35e181" content-type="local-data"><caption><title>Author's manuscript</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="bmjopen-2013-002665.draft_revisions.pdf"/></supplementary-material><supplementary-material id="d35e182" content-type="local-data"><caption><title>Reviewer comments</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="bmjopen-2013-002665.reviewer_comments.pdf"/></supplementary-material></sec></body><back><ack><p>The authors thank the staff of the Sixth and Eighth Core Labs, Department of Medical Research, and the Internal Medicine Lab of Immunology, National Taiwan University Hospital for their technical support.</p></ack><fn-group><fn><p><bold>Contributors:</bold> J-YW and S-CH designed the study. C-YS, C-LY, S-CH, J-YW and L-NL all contributed to the manuscript writing and data interpretation. C-YS and J-YW were involved in the statistical analysis. C-JY was directly responsible for the general organisation and instruction. All authors have read and approved the final manuscript.</p></fn><fn><p><bold>Funding:</bold> This study was supported by the National Science Council, Taiwan (grant NSC 101-2325-B-002-008) and the Research Centre for Biotechnology and Medicine Policy (grant DOH-101-DC-1101). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.</p></fn><fn><p><bold>Competing interests:</bold> None.</p></fn><fn><p><bold>Ethics approval:</bold> The study was approved by the Institutional Review Board of the hospital (NTUH REC: 9561707008).</p></fn><fn><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn><p><bold>Data sharing statement:</bold> No additional data are available.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elkayam</surname><given-names>O</given-names></name><name><surname>Caspi</surname><given-names>D</given-names></name><name><surname>Lidgi</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Auto-antibody profiles in patients with active pulmonary tuberculosis</article-title>. <source>Int J Tuberc Lung Dis</source>
<year>2007</year>;<volume>11</volume>:<fpage>306</fpage>&#x02013;<lpage>10</lpage><pub-id pub-id-type="pmid">17352097</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adebajo</surname><given-names>AO</given-names></name><name><surname>Charles</surname><given-names>P</given-names></name><name><surname>Maini</surname><given-names>RN</given-names></name><etal/></person-group>
<article-title>Autoantibodies in malaria, tuberculosis and hepatitis B in a west African population</article-title>. <source>Clin Exp Immunol</source>
<year>1993</year>;<volume>92</volume>:<fpage>73</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="pmid">8467567</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganesh</surname><given-names>R</given-names></name><name><surname>Ramalingam</surname><given-names>V</given-names></name><name><surname>Eswara Raja</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Antinuclear antibodies in Mycobacterium tuberculosis infection</article-title>. <source>Indian J Pediatr</source>
<year>2008</year>;<volume>75</volume>:<fpage>1188</fpage><pub-id pub-id-type="pmid">18810350</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasikovic-Lecic</surname><given-names>S</given-names></name><name><surname>Kerenji</surname><given-names>A</given-names></name><name><surname>Pavlovic</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Autoantibodies in patients treated for active pulmonary tuberculosis</article-title>. <source>Med Pregl</source>
<year>2008</year>;<volume>61</volume>:<fpage>333</fpage>&#x02013;<lpage>42</lpage><pub-id pub-id-type="pmid">19097368</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aletaha</surname><given-names>D</given-names></name><name><surname>Neogi</surname><given-names>T</given-names></name><name><surname>Silman</surname><given-names>AJ</given-names></name><etal/></person-group>
<article-title>2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative</article-title>. <source>Ann Rheum Dis</source>
<year>2010</year>;<volume>69</volume>:<fpage>1580</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="pmid">20699241</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rantapaa-Dahlqvist</surname><given-names>S</given-names></name><name><surname>de Jong</surname><given-names>BA</given-names></name><name><surname>Berglin</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source>
<year>2003</year>;<volume>48</volume>:<fpage>2741</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="pmid">14558078</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Lu</surname><given-names>K-T</given-names></name></person-group>, <edition>eds</edition>
<source>Taiwan guidelines for TB diagnosis and treatment</source>. <publisher-loc>Taipei, Taiwan</publisher-loc>: <publisher-name>Centers for Disease Control, R.O.C. (Taiwan)</publisher-name>, <year>2011</year></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laniado-Laborin</surname><given-names>R</given-names></name><name><surname>Cabrales-Vargas</surname><given-names>N</given-names></name></person-group>
<article-title>Tuberculosis in healthcare workers at a general hospital in Mexico</article-title>. <source>Infect Control Hosp Epidemiol</source>
<year>2006</year>;<volume>27</volume>:<fpage>449</fpage>&#x02013;<lpage>52</lpage><pub-id pub-id-type="pmid">16671024</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JY</given-names></name><name><surname>Shu</surname><given-names>CC</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><etal/></person-group>
<article-title>Interferon-gamma release assay and Rifampicin therapy for household contacts of tuberculosis</article-title>. <source>J Infect</source>
<year>2012</year>;<volume>64</volume>:<fpage>291</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="pmid">22207002</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>N</given-names></name><name><surname>Koshiba</surname><given-names>M</given-names></name><name><surname>Nishimura</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period</article-title>. <source>Mod Rheumatol</source>
<year>2008</year>;<volume>18</volume>:<fpage>153</fpage>&#x02013;<lpage>60</lpage><pub-id pub-id-type="pmid">18283522</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RM</given-names></name><name><surname>Lipsky</surname><given-names>PE</given-names></name></person-group>
<article-title>Autoimmunity</article-title>. In: <person-group person-group-type="editor"><name><surname>Firestein</surname><given-names>MGS</given-names></name><name><surname>Budd</surname><given-names>RC</given-names></name><name><surname>Harris</surname><given-names>ED</given-names><suffix>Jr</suffix></name><name><surname>McInnes</surname><given-names>IB</given-names></name><name><surname>Ruddy</surname><given-names>S</given-names></name><name><surname>Sergent</surname><given-names>JS</given-names></name></person-group><comment>MD</comment> eds. <source>Kelley's textbook of rheumatology</source>. <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Elsevier Inc</publisher-name>, <year>2009</year>:<fpage>270</fpage></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>AM</given-names></name><name><surname>Black</surname><given-names>MM</given-names></name></person-group>
<article-title>Epitope spreading: protection from pathogens, but propagation of autoimmunity?</article-title>
<source>Clin Exp Dermatol</source>
<year>2001</year>;<volume>26</volume>:<fpage>427</fpage>&#x02013;<lpage>33</lpage><pub-id pub-id-type="pmid">11488833</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>SL</given-names></name><name><surname>Craft</surname><given-names>JE</given-names></name></person-group>
<article-title>Antinuclear antibodies</article-title>. In <person-group person-group-type="editor"><name><surname>Firestein</surname><given-names>MGS</given-names></name><name><surname>Budd</surname><given-names>RC</given-names></name><name><surname>Harris</surname><given-names>ED Jr</given-names></name><name><surname>Mclnnes</surname><given-names>IB</given-names></name><name><surname>Ruddy</surname><given-names>S</given-names></name><name><surname>Sergent</surname><given-names>JS, MD</given-names></name></person-group> eds. <source>Kelley's textbook of rheumatology</source>. <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Elsevier</publisher-name>, <year>2009</year>:<fpage>1623</fpage></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tassiulas</surname><given-names>IO</given-names></name><name><surname>Boumpas</surname><given-names>DT</given-names></name></person-group>
<article-title>Clinical features and treatment of systemic lupus erythematosus</article-title>. In: <person-group person-group-type="editor"><name><surname>Firestein</surname><given-names>MGS</given-names></name><name><surname>Budd</surname><given-names>RC</given-names></name><name><surname>Harris</surname><given-names>ED Jr</given-names></name><name><surname>Mclnnes</surname><given-names>IB</given-names></name><name><surname>Ruddy</surname><given-names>S</given-names></name><name><surname>Sergent</surname><given-names>JS, MD</given-names></name></person-group> eds. <source>Kelley's textbook of theumatology</source>. <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Elsevier</publisher-name>, <year>2009</year>:<fpage>1273</fpage></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>KA</given-names></name><name><surname>Kulik</surname><given-names>L</given-names></name><name><surname>Tomooka</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis</article-title>. <source>J Clin Invest</source>
<year>2006</year>;<volume>116</volume>:<fpage>961</fpage>&#x02013;<lpage>73</lpage><pub-id pub-id-type="pmid">16585962</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Varga</surname><given-names>J</given-names></name><name><surname>Denton</surname><given-names>CP</given-names></name></person-group>
<article-title>Systemic sclerosis and the scleroderma-spectrum disorders</article-title>. In: <person-group person-group-type="editor"><name><surname>Firestein</surname><given-names>MGS</given-names></name><name><surname>Budd</surname><given-names>RC</given-names></name><name><surname>Harris</surname><given-names>ED Jr</given-names></name><name><surname>Mclnnes</surname><given-names>IB</given-names></name><name><surname>Ruddy</surname><given-names>S</given-names></name><name><surname>Sergent</surname><given-names>JS, MD</given-names></name></person-group> eds. <source>Kelley's textbook of rheumatology</source>. <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Elsevier</publisher-name>, <year>2009</year>:<fpage>1323</fpage></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Nagaraju</surname><given-names>K</given-names></name><name><surname>Lundberg</surname><given-names>IE</given-names></name></person-group>
<article-title>Inflammatory disease of muscle and other myopathies</article-title>. In: <person-group person-group-type="editor"><name><surname>Firestein</surname><given-names>MGS</given-names></name><name><surname>Budd</surname><given-names>RC</given-names></name><name><surname>Harris</surname><given-names>ED Jr</given-names></name><name><surname>Mclnnes</surname><given-names>IB</given-names></name><name><surname>Ruddy</surname><given-names>S</given-names></name><name><surname>Sergent</surname><given-names>JS, MD</given-names></name></person-group> eds. <source>Kelley's textbook of rheumatology</source>. <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Elsevier</publisher-name>, <year>2009</year>:<fpage>1356</fpage></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JS</given-names></name><name><surname>Sexton</surname><given-names>DJ</given-names></name><name><surname>Mick</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis</article-title>. <source>Clin Infect Dis</source>
<year>2000</year>;<volume>30</volume>:<fpage>633</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="pmid">10770721</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyakis</surname><given-names>S</given-names></name><name><surname>Lockshin</surname><given-names>MD</given-names></name><name><surname>Atsumi</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)</article-title>. <source>J Thromb Haemost</source>
<year>2006</year>;<volume>4</volume>:<fpage>295</fpage>&#x02013;<lpage>306</lpage><pub-id pub-id-type="pmid">16420554</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faldt</surname><given-names>J</given-names></name><name><surname>Dahlgren</surname><given-names>C</given-names></name><name><surname>Karlsson</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Activation of human neutrophils by mycobacterial phenolic glycolipids</article-title>. <source>Clin Exp Immunol</source>
<year>1999</year>;<volume>118</volume>:<fpage>253</fpage>&#x02013;<lpage>60</lpage><pub-id pub-id-type="pmid">10540187</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasser</surname><given-names>O</given-names></name><name><surname>Hess</surname><given-names>C</given-names></name><name><surname>Miot</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Characterisation and properties of ectosomes released by human polymorphonuclear neutrophils</article-title>. <source>Exp Cell Res</source>
<year>2003</year>;<volume>285</volume>:<fpage>243</fpage>&#x02013;<lpage>57</lpage><pub-id pub-id-type="pmid">12706119</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>LR</given-names></name><name><surname>Dier</surname><given-names>KJ</given-names></name><name><surname>Lopez</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome</article-title>. <source>Am J Clin Pathol</source>
<year>2004</year>;<volume>121</volume>:<fpage>142</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="pmid">14750252</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galli</surname><given-names>M</given-names></name><name><surname>Comfurius</surname><given-names>P</given-names></name><name><surname>Maassen</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor</article-title>. <source>Lancet</source>
<year>1990</year>;<volume>335</volume>:<fpage>1544</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="pmid">1972485</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deane</surname><given-names>KD</given-names></name><name><surname>West</surname><given-names>SG</given-names></name></person-group>
<article-title>Antiphospholipid antibodies as a cause of pulmonary capillaritis and diffuse alveolar hemorrhage: a case series and literature review</article-title>. <source>Semin Arthritis Rheum</source>
<year>2005</year>;<volume>35</volume>:<fpage>154</fpage>&#x02013;<lpage>65</lpage><pub-id pub-id-type="pmid">16325656</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almerico Marruchella</surname><given-names>AC</given-names></name><name><surname>Tommasi</surname><given-names>C</given-names></name><name><surname>Lauria</surname><given-names>FN</given-names></name><etal/></person-group> &#x000a0;<article-title>A case of pulmonary tuberculosis presenting as diffuse alveolar haemorrhage: is there a role for anticardiolipin antibodies?</article-title>
<source>BMC Infect Dis</source>
<year>2010</year>;<volume>10</volume>:<fpage>33</fpage><pub-id pub-id-type="pmid">20170532</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erkan</surname><given-names>D</given-names></name><name><surname>Lockshin</surname><given-names>MD</given-names></name></person-group>
<article-title>Non-criteria manifestations of antiphospholipid syndrome</article-title>. <source>Lupus</source>
<year>2010</year>;<volume>19</volume>:<fpage>424</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="pmid">20353981</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guldner</surname><given-names>HH</given-names></name><name><surname>Szostecki</surname><given-names>C</given-names></name><name><surname>Vosberg</surname><given-names>HP</given-names></name><etal/></person-group>
<article-title>Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I.</article-title>
<source>Chromosoma</source>
<year>1986</year>;<volume>94</volume>:<fpage>132</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="pmid">2428564</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shero</surname><given-names>JH</given-names></name><name><surname>Bordwell</surname><given-names>B</given-names></name><name><surname>Rothfield</surname><given-names>NF</given-names></name><etal/></person-group>
<article-title>High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients</article-title>. <source>Science</source>
<year>1986</year>;<volume>231</volume>:<fpage>737</fpage>&#x02013;<lpage>40</lpage><pub-id pub-id-type="pmid">3003910</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizou</surname><given-names>C</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>Panou-Pomonis</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>B-Cell epitope mapping of DNA topoisomerase I defines epitopes strongly associated with pulmonary fibrosis in systemic sclerosis</article-title>. <source>Am J Respir Cell Mol Biol</source>
<year>2000</year>;<volume>22</volume>:<fpage>344</fpage>&#x02013;<lpage>51</lpage><pub-id pub-id-type="pmid">10696071</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annamalai</surname><given-names>T</given-names></name><name><surname>Dani</surname><given-names>N</given-names></name><name><surname>Cheng</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Analysis of DNA relaxation and cleavage activities of recombinant Mycobacterium tuberculosis DNA topoisomerase I from a new expression and purification protocol</article-title>. <source>BMC Biochem</source>
<year>2009</year>;<volume>10</volume>:<fpage>18</fpage><pub-id pub-id-type="pmid">19519900</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narula</surname><given-names>G</given-names></name><name><surname>Becker</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>The DNA relaxation activity and covalent complex accumulation of Mycobacterium tuberculosis topoisomerase I can be assayed in Escherichia coli: application for identification of potential FRET-dye labeling sites</article-title>. <source>BMC Biochem</source>
<year>2010</year>;<volume>11</volume>:<fpage>41</fpage><pub-id pub-id-type="pmid">20920291</pub-id></mixed-citation></ref></ref-list></back></article>